Mylan Reports Launch Of Generic Viramune XR Extended-Release Tablets, 100 Mg

(RTTNews) - Mylan N.V. (MYL) announced the U.S. launch of Nevirapine Extended-release Tablets, 100 mg, the generic version of Boehringer Ingelheim's Viramune XR.

Mylan received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for this product, which is used in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and in children 6 to less than 18 years of age.

The launch adds to Mylan's growing portfolio of ARV medicines across the globe. About 50 percent of those being treated for HIV/AIDS in the developing world rely on a Mylan product.

Nevirapine Extended-release Tablets, 100 mg, had U.S. sales of $67 thousand for the 12 months ending Sept. 30, 2015, according to IMS Health.